THE POSSIBILITITES OF OUR TECHNOLOGY PLATFORM ARE ENDLESS
We also see potential applications in oncology (immunotherapy) for personalization of small molecules treatments.
Our technology can replicate the tumor matrix conditions and evaluate both enhancement an inhibition of immune cell responses by small molecules.
Future development of our technology can potentially personalize and monitor systemic response to immunotherapy.
The test could be used for:
PD1 / PD-L1 Inhibitors
Combinations of immunomodulators
Some pharmaceutical companies have already introduced new CDx test for PD-L1 inhibitors -i.e. Keytruda or Tecentriq. The possibilities of personalizing immunotherapies are immense.